Navigation Links
Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/14/2011

MONMOUTH JUNCTION, N.J., Nov. 14, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011, at 8:30 AM ET, in New York.

A live audio webcast will be available on Insmed's website, http://www.insmed.com.  The webcast will also be archived for 90 days.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with high unmet medical need.  Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934.  Investors are cautioned that such statements in this release, including statements relating to our financial position, results of operations, the status and the results of preclinical studies and clinical trials and preclinical and clinical data described herein, the timing of responses to information and data requests from FDA, the development of our products, and the business strategies, evaluations, plans, and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by such factors as the receipt and timing of FDA and other regulatory reviews and approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may experience unexpected regulatory actions, delays or requests, our future clinical trials may not be successful, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Brian Ritchie – FTI Consulting
212-850-5683
brian.ritchie@fticonsulting.com

Media Contact:
Irma Gomez-Dib – FTI Consulting
212-850-5761
irma.gomez-dib@fticonsulting.com


'/>"/>
SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
9. Insmed to Host Third Quarter 2010 Conference Call
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
11. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)...  Socionext Inc. and SOINN Inc. today announced ... which Socionext extracts and delivers biometrics data to ... results in reading ultrasound images from Socionext,s viewphii™ ... results will be introduced at Medtec Japan, held ... 4505 & 4507. In this initial ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... The Patient Advocacy Community of The Beryl Institute presented Eve ... Ravich Patient Advocacy Award in recognition of her extraordinary contributions to the field ... at The Beryl Institute’s annual Patient Experience Conference on March 20 in ...
(Date:4/21/2017)... Sterling, VA (PRWEB) , ... April 21, 2017 ... ... hosting its first weeklong campaign, AWARE: A Week of Addiction and Recovery Education, ... emerging evidence in treating and preventing substance use disorders. , The mission ...
(Date:4/21/2017)... Malvern, Worcestershire, UK (PRWEB) , ... April 21, ... ... Queen’s Award for Enterprise in the category of International Trade, the UK’s most ... performance in international trade, which represents 95% of total revenues and has grown ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Westside ... experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become one ... to help my numerous clients over the years with all their dental needs,” said ...
(Date:4/21/2017)... ... 21, 2017 , ... Federal mandate, fines, controversy, questions about ... Obamacare program that most Republicans love to hate and Texas Agriculture Commissioner Sid ... , Like Obamacare, the Miller program centers upon a federal mandate. ...
Breaking Medicine News(10 mins):